Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Jejunal wall delivery of insulin via an ingestible capsule in anesthetized swine-A pharmacokinetic and pharmacodynamic study.

Hashim M, Korupolu R, Syed B, Horlen K, Beraki S, Karamchedu P, Dhalla AK, Ruffy R, Imran M.

Pharmacol Res Perspect. 2019 Oct;7(5):e00522. doi: 10.1002/prp2.522.

2.

Discovery of Dihydrobenzoxazepinone (GS-6615) Late Sodium Current Inhibitor (Late INai), a Phase II Agent with Demonstrated Preclinical Anti-Ischemic and Antiarrhythmic Properties.

Zablocki JA, Elzein E, Li X, Koltun DO, Parkhill EQ, Kobayashi T, Martinez R, Corkey B, Jiang H, Perry T, Kalla R, Notte GT, Saunders O, Graupe M, Lu Y, Venkataramani C, Guerrero J, Perry J, Osier M, Strickley R, Liu G, Wang WQ, Hu L, Li XJ, El-Bizri N, Hirakawa R, Kahlig K, Xie C, Li CH, Dhalla AK, Rajamani S, Mollova N, Soohoo D, Lepist EI, Murray B, Rhodes G, Belardinelli L, Desai MC.

J Med Chem. 2016 Oct 13;59(19):9005-9017. doi: 10.1021/acs.jmedchem.6b00939. Epub 2016 Oct 3.

PMID:
27690427
3.

Discovery of triazolopyridine GS-458967, a late sodium current inhibitor (Late INai) of the cardiac NaV 1.5 channel with improved efficacy and potency relative to ranolazine.

Koltun DO, Parkhill EQ, Elzein E, Kobayashi T, Notte GT, Kalla R, Jiang RH, Li X, Perry TD, Avila B, Wang WQ, Smith-Maxwell C, Dhalla AK, Rajamani S, Stafford B, Tang J, Mollova N, Belardinelli L, Zablocki JA.

Bioorg Med Chem Lett. 2016 Jul 1;26(13):3202-3206. doi: 10.1016/j.bmcl.2016.03.101. Epub 2016 Mar 30.

PMID:
27080178
4.

Discovery of triazolopyridinone GS-462808, a late sodium current inhibitor (Late INai) of the cardiac Nav1.5 channel with improved efficacy and potency relative to ranolazine.

Koltun DO, Parkhill EQ, Elzein E, Kobayashi T, Jiang RH, Li X, Perry TD, Avila B, Wang WQ, Hirakawa R, Smith-Maxwell C, Wu L, Dhalla AK, Rajamani S, Mollova N, Stafford B, Tang J, Belardinelli L, Zablocki JA.

Bioorg Med Chem Lett. 2016 Jul 1;26(13):3207-3211. doi: 10.1016/j.bmcl.2016.03.096. Epub 2016 Mar 26.

PMID:
27038498
5.

Inhibition of late Na+ current, a novel target to improve diastolic function and electrical abnormalities in Dahl salt-sensitive rats.

Chi L, Belardinelli L, Zeng A, Hirakawa R, Rajamani S, Ling H, Dhalla AK.

Am J Physiol Heart Circ Physiol. 2016 May 15;310(10):H1313-20. doi: 10.1152/ajpheart.00863.2015. Epub 2016 Mar 18.

6.

Ranolazine reduces remodeling of the right ventricle and provoked arrhythmias in rats with pulmonary hypertension.

Liles JT, Hoyer K, Oliver J, Chi L, Dhalla AK, Belardinelli L.

J Pharmacol Exp Ther. 2015 Jun;353(3):480-9. doi: 10.1124/jpet.114.221861. Epub 2015 Mar 13.

PMID:
25770134
7.

Blockade of Na+ channels in pancreatic α-cells has antidiabetic effects.

Dhalla AK, Yang M, Ning Y, Kahlig KM, Krause M, Rajamani S, Belardinelli L.

Diabetes. 2014 Oct;63(10):3545-56. doi: 10.2337/db13-1562. Epub 2014 May 8.

8.

The beneficial effects of ranolazine on cardiac function after myocardial infarction are greater in diabetic than in nondiabetic rats.

Mourouzis I, Mantzouratou P, Galanopoulos G, Kostakou E, Dhalla AK, Belardinelli L, Pantos C.

J Cardiovasc Pharmacol Ther. 2014 Sep;19(5):457-69. doi: 10.1177/1074248414524481. Epub 2014 Mar 19.

PMID:
24651516
9.

Selective inhibition of the late sodium current has no adverse effect on electrophysiological or contractile function of the normal heart.

Fernandes S, Hoyer K, Liu G, Wang WQ, Dhalla AK, Belardinelli L, Rajamani S.

J Cardiovasc Pharmacol. 2014 Jun;63(6):512-9. doi: 10.1097/FJC.0000000000000075.

PMID:
24406487
10.

Reduction of free fatty acids, safety, and pharmacokinetics of oral GS-9667, an A(1) adenosine receptor partial agonist.

Staehr PM, Dhalla AK, Zack J, Wang X, Ho YL, Bingham J, Belardinelli L.

J Clin Pharmacol. 2013 Apr;53(4):385-92. doi: 10.1002/jcph.9. Epub 2013 Feb 20.

PMID:
23427000
11.

A novel, potent, and selective inhibitor of cardiac late sodium current suppresses experimental arrhythmias.

Belardinelli L, Liu G, Smith-Maxwell C, Wang WQ, El-Bizri N, Hirakawa R, Karpinski S, Li CH, Hu L, Li XJ, Crumb W, Wu L, Koltun D, Zablocki J, Yao L, Dhalla AK, Rajamani S, Shryock JC.

J Pharmacol Exp Ther. 2013 Jan;344(1):23-32. doi: 10.1124/jpet.112.198887. Epub 2012 Sep 25.

PMID:
23010360
12.

Adenosine A₁ receptors do not play a major role in the regulation of lipogenic gene expression in hepatocytes.

Yang M, Chu R, Chisholm JW, Doege H, Belardinelli L, Dhalla AK.

Eur J Pharmacol. 2012 May 15;683(1-3):332-9. doi: 10.1016/j.ejphar.2012.03.012. Epub 2012 Mar 16.

PMID:
22449383
13.

Ranolazine increases β-cell survival and improves glucose homeostasis in low-dose streptozotocin-induced diabetes in mice.

Ning Y, Zhen W, Fu Z, Jiang J, Liu D, Belardinelli L, Dhalla AK.

J Pharmacol Exp Ther. 2011 Apr;337(1):50-8. doi: 10.1124/jpet.110.176396. Epub 2011 Jan 12.

PMID:
21228065
14.

Effect of ranolazine on A1C and glucose levels in hyperglycemic patients with non-ST elevation acute coronary syndrome.

Chisholm JW, Goldfine AB, Dhalla AK, Braunwald E, Morrow DA, Karwatowska-Prokopczuk E, Belardinelli L.

Diabetes Care. 2010 Jun;33(6):1163-8. doi: 10.2337/dc09-2334. Epub 2010 Mar 31.

15.

Ranolazine as a cardioplegia additive improves recovery of diastolic function in isolated rat hearts.

Hwang H, Arcidi JM Jr, Hale SL, Simkhovich BZ, Belardinelli L, Dhalla AK, Shryock JC, Kloner RA.

Circulation. 2009 Sep 15;120(11 Suppl):S16-21. doi: 10.1161/CIRCULATIONAHA.108.844167.

PMID:
19752362
16.

Ranolazine, an antianginal agent, markedly reduces ventricular arrhythmias induced by ischemia and ischemia-reperfusion.

Dhalla AK, Wang WQ, Dow J, Shryock JC, Belardinelli L, Bhandari A, Kloner RA.

Am J Physiol Heart Circ Physiol. 2009 Nov;297(5):H1923-9. doi: 10.1152/ajpheart.00173.2009. Epub 2009 Sep 18.

17.

A1 adenosine receptor: role in diabetes and obesity.

Dhalla AK, Chisholm JW, Reaven GM, Belardinelli L.

Handb Exp Pharmacol. 2009;(193):271-95. doi: 10.1007/978-3-540-89615-9_9. Review.

PMID:
19639285
18.

Ranolazine as an adjunct to cardioplegia: a potential new therapeutic application.

Hwang H, Arcidi JM Jr, Hale SL, Simkhovich BZ, Belardinelli L, Dhalla AK, Shryock JC, Kloner RA.

J Cardiovasc Pharmacol Ther. 2009 Jun;14(2):125-33. doi: 10.1177/1074248409333491. Epub 2009 Mar 27.

PMID:
19329672
19.

Partial A1 adenosine receptor agonist regulates cardiac substrate utilization in insulin-resistant rats in vivo.

Shearer J, Severson DL, Su L, Belardinelli L, Dhalla AK.

J Pharmacol Exp Ther. 2009 Jan;328(1):306-11. doi: 10.1124/jpet.108.143594. Epub 2008 Oct 24.

PMID:
18952888
20.

Comparison of the antilipolytic effects of an A1 adenosine receptor partial agonist in normal and diabetic rats.

Dhalla AK, Santikul M, Chisholm JW, Belardinelli L, Reaven GM.

Diabetes Obes Metab. 2009 Feb;11(2):95-101. doi: 10.1111/j.1463-1326.2008.00902.x. Epub 2008 May 20.

PMID:
18494808
21.

Antitorsadogenic effects of ({+/-})-N-(2,6-dimethyl-phenyl)-(4[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazine (ranolazine) in anesthetized rabbits.

Wang WQ, Robertson C, Dhalla AK, Belardinelli L.

J Pharmacol Exp Ther. 2008 Jun;325(3):875-81. doi: 10.1124/jpet.108.137729. Epub 2008 Mar 5.

PMID:
18322148
22.

A1 adenosine receptor partial agonist lowers plasma FFA and improves insulin resistance induced by high-fat diet in rodents.

Dhalla AK, Wong MY, Voshol PJ, Belardinelli L, Reaven GM.

Am J Physiol Endocrinol Metab. 2007 May;292(5):E1358-63. Epub 2007 Jan 16.

23.

Antilipolytic activity of a novel partial A1 adenosine receptor agonist devoid of cardiovascular effects: comparison with nicotinic acid.

Dhalla AK, Santikul M, Smith M, Wong MY, Shryock JC, Belardinelli L.

J Pharmacol Exp Ther. 2007 Apr;321(1):327-33. Epub 2007 Jan 4.

PMID:
17204748
24.

A novel partial agonist of the A(1)-adenosine receptor and evidence of receptor homogeneity in adipocytes.

Fatholahi M, Xiang Y, Wu Y, Li Y, Wu L, Dhalla AK, Belardinelli L, Shryock JC.

J Pharmacol Exp Ther. 2006 May;317(2):676-84. Epub 2006 Jan 12.

PMID:
16410404
25.

Tachycardia caused by A2A adenosine receptor agonists is mediated by direct sympathoexcitation in awake rats.

Dhalla AK, Wong MY, Wang WQ, Biaggioni I, Belardinelli L.

J Pharmacol Exp Ther. 2006 Feb;316(2):695-702. Epub 2005 Oct 14.

PMID:
16227469
26.

Pharmacology and therapeutic applications of A1 adenosine receptor ligands.

Dhalla AK, Shryock JC, Shreeniwas R, Belardinelli L.

Curr Top Med Chem. 2003;3(4):369-85. Review.

PMID:
12570756
27.

Characterization of an NBTI-sensitive equilibrative nucleoside transporter in vascular smooth muscle.

Dhalla AK, Dodam JR, Jones AW, Rubin LJ.

J Mol Cell Cardiol. 2001 Jun;33(6):1143-52.

PMID:
11444919
28.

Selective transport of adenosine into porcine coronary smooth muscle.

Rubin LJ, Johnson LR, Dodam JR, Dhalla AK, Magliola L, Laughlin MH, Jones AW.

Am J Physiol Heart Circ Physiol. 2000 Sep;279(3):H1397-410.

29.

Inhibition of tissue repair by spironolactone: role of mineralocorticoids in fibrous tissue formation.

Slight SH, Chilakamarri VK, Nasr S, Dhalla AK, Ramires FJ, Sun Y, Ganjam VK, Weber KT.

Mol Cell Biochem. 1998 Dec;189(1-2):47-54.

PMID:
9879653
30.

chk-YB-1b, a Y-box binding protein activates transcription from rat alpha1(I) procollagen gene promoter.

Dhalla AK, Ririe SS, Swamynathan SK, Weber KT, Guntaka RV.

Biochem J. 1998 Dec 1;336 ( Pt 2):373-9.

31.

Pouch tissue and angiotensin peptide generation.

Katwa LC, Sun Y, Campbell SE, Tyagi SC, Dhalla AK, Kandala JC, Weber KT.

J Mol Cell Cardiol. 1998 Jul;30(7):1401-13.

PMID:
9710808
32.

Identification of negative and positive regulatory elements in the rat alpha 1(I) collagen gene promoter.

Dhalla AK, Kandala JC, Weber KT, Guntaka RV.

Int J Biochem Cell Biol. 1997 Jan;29(1):143-51.

PMID:
9076949
33.

Anti-free radical mechanisms in captopril protection against reperfusion injury in isolated rat hearts.

Anderson B, Khaper N, Dhalla AK, Singal PK.

Can J Cardiol. 1996 Oct;12(10):1099-104.

PMID:
9191504
34.

Complete stunning in hypertrophied guinea pig heart. Defects in sarcolemmal calcium influx.

Dhalla AK, Khaper N, Singal PK.

Ann N Y Acad Sci. 1996 Sep 30;793:142-55.

PMID:
8906162
35.

Role of oxidative stress in transition of hypertrophy to heart failure.

Dhalla AK, Hill MF, Singal PK.

J Am Coll Cardiol. 1996 Aug;28(2):506-14.

36.

Oxidative stress and heart failure.

Singh N, Dhalla AK, Seneviratne C, Singal PK.

Mol Cell Biochem. 1995 Jun 7-21;147(1-2):77-81. Review.

PMID:
7494558
37.

Antioxidant changes in hypertrophied and failing guinea pig hearts.

Dhalla AK, Singal PK.

Am J Physiol. 1994 Apr;266(4 Pt 2):H1280-5.

PMID:
8184905
38.

Endogenous antioxidant changes in the myocardium in response to acute and chronic stress conditions.

Singal PK, Dhalla AK, Hill M, Thomas TP.

Mol Cell Biochem. 1993 Dec 22;129(2):179-86. Review.

PMID:
8177240

Supplemental Content

Loading ...
Support Center